Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mellitus.

Autor: Vesell ES; Department of Pharmacology, MC H078, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA. esv1@psu.edu, Beyer KH Jr

Publikováno v: Toxicology [Toxicology] 2000 Apr 03; Vol. 144 (1-3), pp. 5-11.

Pyrazinoylguanidine in end-stage renal disease: a prospective, placebo-controlled pilot study.

Autor: Ahsan N; Department of Medicine, The Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA., Korsunsky Z, Beyer KH Jr, Vesell ES

Publikováno v: Pharmacology [Pharmacology] 1998 Aug; Vol. 57 (2), pp. 96-103.

Studies on pyrazinoylguanidine. 5. Temporal effects over 24 weeks demonstrating attenuation of diabetic nephropathy in STZ-diabetic rats.

Autor: Follansbee MH; Department of Pharmacology, Pennsylvania State University, College of Medicine, Hershey 17033, USA., Beyer KH Jr, Griffith JW, Vesell ES

Publikováno v: Pharmacology [Pharmacology] 1997 May; Vol. 54 (5), pp. 241-55.

Studies on pyrazinoylguanidine. 4. Upregulation of phosphodiesterase activity in rat adipose tissue and downregulation of gluconeogenesis and adenosine 3',5'-monophosphate concentrations in perfused rat liver.

Autor: A-Rahim YI; Department of Pharmacology, Pennsylvania State University, College of Medicine, Hershey 17033, USA., Rannels SL, Kimball SR, Beyer KH Jr, Vesell ES

Publikováno v: Pharmacology [Pharmacology] 1996 Oct; Vol. 53 (4), pp. 211-8.

Studies on pyrazinoylguanidine. 2. Comparative drug and dose effects on glucose and lipid metabolism in streptozotocin-induced diabetic rats.

Autor: A-Rahim YI; Department of Pharmacology, Pennsylvania State University, College of Medicine, Hershey 17033, USA., Beyer KH Jr, Vesell ES

Publikováno v: Pharmacology [Pharmacology] 1996 Mar; Vol. 52 (3), pp. 145-52.